Workflow
Clinical Laboratories
icon
Search documents
Here’s Alger Weatherbie Specialized Growth Fund’s Comment on NeoGenomics (NEO)
Yahoo Finance· 2025-09-24 13:10
Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Initial volatility in April stemmed from increased trade policy uncertainty following President Trump's tariffs on April 2, which affected import-dependent companies. Stability returned on April 9 after a 90-day pause on new duties. Market sentiment improved in May following the White House’s suspension of reciproca ...
Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration
Prnewswire· 2025-09-23 11:07
Core Insights - Quest Diagnostics and Epic have announced a collaboration aimed at enhancing the laboratory testing experience for healthcare providers and patients in the United States [1][2][3] Group 1: Collaboration Details - The partnership will support Project Nova, a multi-year initiative by Quest to simplify and improve customer-facing processes, enhancing experiences for patients and providers across various EHR platforms [2][5] - Epic's Diagnostic Enterprise system will be integrated into Quest's national laboratory operations, including technologies like Aura, Beaker Laboratory, and MyChart [2][3] Group 2: Expected Benefits - Customers can expect faster and more convenient services, improved access to health insights, and quicker turnaround times for testing services [4][7] - The collaboration aims to streamline systems related to lab ordering, results reporting, and patient appointment scheduling, enhancing overall operational efficiency [7] Group 3: Leadership and Implementation - A cross-organization team experienced in large-scale implementations will oversee a phased rollout, ensuring a smooth transition for health systems and providers [5] - The focus will be on creating a comprehensive test list and improving patient engagement through MyChart [3][5]
Here's Why Labcorp Holdings (LH) is a Strong Growth Stock
ZACKS· 2025-09-16 14:45
Core Viewpoint - Zacks Premium offers various tools and resources to help investors make informed decisions and enhance their confidence in stock market investments [1]. Summary by Category Zacks Style Scores - Zacks Style Scores are indicators designed to assist investors in selecting stocks with the highest potential to outperform the market within the next 30 days, rated from A to F based on value, growth, and momentum characteristics [2]. Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow, aiming to find attractive investment opportunities before the market recognizes their true value [3]. Growth Score - The Growth Style Score emphasizes a company's financial health and future growth potential, analyzing projected and historical earnings, sales, and cash flow to identify stocks with sustainable long-term growth [4]. Momentum Score - The Momentum Style Score helps investors capitalize on price trends, utilizing metrics like one-week price changes and monthly earnings estimate changes to determine optimal entry points for stocks [5]. VGM Score - The VGM Score combines the Value, Growth, and Momentum Scores, providing a comprehensive assessment of stocks based on their weighted styles, thus identifying companies with the best overall investment potential [6]. Zacks Rank - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.64% since 1988, significantly outperforming the S&P 500 [7][8]. Stock to Watch: Labcorp Holdings - Labcorp Holdings, a leading healthcare diagnostics company, has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating strong growth potential. The company is projected to achieve year-over-year earnings growth of 11.9% for the current fiscal year, with upward revisions in earnings estimates from analysts [11][12].
Here's Why Labcorp Holdings (LH) is a Strong Value Stock
ZACKS· 2025-08-15 14:41
Company Overview - Labcorp Holdings, headquartered in Burlington, NC, is a leading healthcare diagnostics company that provides comprehensive clinical laboratory services and end-to-end drug development support [12] - In 2015, Labcorp acquired Covance, a drug development services company that offers a wide range of early-stage and late-stage product development services primarily to the pharmaceutical and biotechnology industries [12] Investment Ratings - Labcorp is currently rated as a 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid overall performance [13] - The company has a Value Style Score of B, supported by attractive valuation metrics such as a forward P/E ratio of 16.64, which may appeal to value investors [13] Earnings Estimates - In the last 60 days, eight analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.25 to $16.30 per share [13] - Labcorp has demonstrated an average earnings surprise of +2.5%, indicating a positive trend in earnings performance [13] Investment Potential - With a solid Zacks Rank and top-tier Value and VGM Style Scores, Labcorp is recommended to be on investors' short list for potential investment opportunities [14]
Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term
ZACKS· 2025-07-29 14:41
Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days. Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Jus ...
Quest Diagnostics(DGX) - 2025 Q2 - Earnings Call Presentation
2025-07-22 12:30
Q2 2025 Performance Strong revenue growth from acquisitions, enterprise accounts, and innovative clinical solutions Q2 2025 15.2% Total revenue $2.76 billion 16.9% Adjusted operating income %2 11.5% Adjusted diluted EPS2 $2.62 per share 1 1,3 Company overview Quest is a leader in diagnostic testing insights and information services. Read our Q2 earnings press release on our Investor Relations site. " Through continued execution of our strategy, we delivered a strong second quarter, with revenues growing 15. ...
Quest Diagnostics Stock Climbs 27.3% in a Year: What's Fueling It?
ZACKS· 2025-07-07 13:01
Core Insights - Quest Diagnostics (DGX) has experienced a significant share price increase of 27.3% over the past year, outperforming the industry and S&P 500 [1][8] - The company is currently rated Zacks Rank 2 (Buy) and is benefiting from investments in Advanced Diagnostics, which enhance patient care and drive growth [2] Company Overview - Headquartered in Secaucus, NJ, Quest Diagnostics provides a wide range of diagnostic information services and serves as a key provider of reference testing for about half of U.S. hospitals [3] - The company aims for annual revenue growth of 1-2% through targeted acquisitions [3] Growth Catalysts - The growth of Quest Diagnostics is primarily driven by its strength in Advanced Diagnostics, particularly in areas such as cardiometabolic, autoimmune, brain health, oncology, and women's health [4] - There is robust demand for Alzheimer's disease risk detection blood tests, and the company plans to introduce new biomarkers for better assessment of dementia [4] - The company has expanded its women's health offerings with a new self-collection option for HPV cervical cancer screening [4] - Quest Diagnostics anticipates revenue generation from its Haystack minimal-residual disease (MRD) test this year [4] Acquisitions and Partnerships - In 2024, the company completed eight acquisitions, including LifeLabs in Canada and Allina Health, to maximize productivity [5] - New health plan partnerships with Elevance Health and Sentara Health Plans are expected to drive volume and revenue gains [6] - Quest Diagnostics became the first independent national lab selected for the Optum Health preferred lab network, gaining access to over 85,000 physicians [6] Operational Efficiency - The company targets 3% annual cost savings and productivity improvements through its Invigorate cost-savings program [9] Financial Estimates - The Zacks Consensus Estimate for Quest Diagnostics' 2025 and 2026 earnings per share (EPS) is projected to increase by 8.6% and 8.2%, reaching $9.70 and $10.50 respectively [11] - Revenues for 2025 are expected to grow by 9.2% to $10.78 billion, followed by a 3.7% increase to $11.19 billion in 2026 [11]
Quest Diagnostics (DGX) FY Conference Transcript
2025-06-03 16:00
Summary of Quest Diagnostics Conference Call Company Overview - **Company**: Quest Diagnostics - **Industry**: Clinical Laboratory Services Key Points and Arguments 1. **Market Strength**: The clinical lab market remains strong, with sustained demand post-COVID, and Quest Diagnostics has a strategy for above-market growth in key channels [3][4] 2. **Revenue Growth Projections**: The company reaffirms a long-term revenue growth outlook of 4% to 5% CAGR and adjusted EPS growth of 7% to 9% [5][73] 3. **Patient Reach**: Quest Diagnostics serves over 50% of U.S. hospitals and physicians, testing over one-third of the U.S. adult population every three years [8][9] 4. **Operational Efficiency**: The company emphasizes productivity, noting that reducing costs directly impacts profit margins, with a focus on continuous improvement [5][8] 5. **Market Segmentation**: The lab market is divided into physician and hospital segments, with Quest targeting the 35% market share held by health systems [11][12][13] 6. **Canadian Market Entry**: Quest entered the Canadian market through the acquisition of LifeLabs, which operates in Ontario and British Columbia, with growth opportunities identified [17][19] 7. **Revenue Sources**: The largest revenue source is the physician channel, followed by hospitals and employer channels, with consumer direct testing being the fastest-growing segment [20][21] 8. **Payer Mix**: The revenue breakdown includes 27% from commercial health plans, with significant contributions from Medicare and Medicaid [22][24] 9. **Macro Trends**: An aging and sicker population drives demand for lab diagnostics, with innovations such as a new blood-based Alzheimer's test contributing to growth [26][27] 10. **Consumer Testing Growth**: The consumer channel allows individuals to order tests directly, catering to privacy seekers and those with chronic conditions [47][48][50] 11. **Life Sciences Revenue**: Quest generates significant revenue from pharmaceutical companies through clinical trials and health care analytics [52][53] 12. **Financial Performance**: The company reported $10 billion in revenue last year, growing 6.7%, with a focus on returning cash to shareholders through dividends and share repurchases [20][72] 13. **M&A Strategy**: Quest aims for 1% to 2% growth from acquisitions annually, with the LifeLabs acquisition being a significant contributor to recent growth [73] Additional Important Content 1. **Technological Advancements**: The company is investing in automation and AI to enhance laboratory operations and improve efficiency [66][68] 2. **Health Trends**: The U.S. population faces significant health challenges, with rising obesity and chronic conditions, which Quest aims to address through its services [29][30][32] 3. **Operational Workforce**: Quest employs approximately 55,000 people, emphasizing the importance of workforce retention and productivity [65] 4. **Testing Innovations**: New tests for oncology, cardiovascular health, and autoimmune disorders are being developed, with a focus on early detection and preventive care [57][60][64] This summary encapsulates the key insights and strategic directions discussed during the Quest Diagnostics conference call, highlighting the company's market position, growth strategies, and operational focus.
Labcorp to Webcast Its Annual Meeting of Shareholders May 15
Prnewswire· 2025-05-08 20:15
Group 1 - Labcorp will host its Annual Meeting of Shareholders on May 15 at 9:00 a.m. ET, which will be available for live streaming on its Investor Relations website [1] - An archived replay of the webcast will be accessible for one year following the event [1] Group 2 - Labcorp is a global leader in laboratory services, providing innovative and comprehensive solutions to healthcare professionals and researchers [2] - The company employs nearly 70,000 individuals and operates in approximately 100 countries [2] - Labcorp supports over 75% of new drugs and therapeutic products approved by the FDA in 2024 and conducts more than 700 million tests annually [2]